SkinBioTherapeutics (SBTX) Stock Statistics & Valuation Metrics

SkinBioTherapeutics has a market cap or net worth of £42.70M. The enterprise value is 38.41M.

SkinBioTherapeutics has 258,779,450 shares outstanding. The number of shares has decreased by -2.65% in one year.

SkinBioTherapeutics’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -67.63%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, SkinBioTherapeutics had revenue of 1.21M and earned -2.88M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -2.20M and capital expenditures -15.85K, giving a free cash flow of -2.22M billion.

SkinBioTherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SkinBioTherapeutics upcoming earnings date is ―, ―.

SkinBioTherapeutics as a current ratio of 0.93, with Debt / Equity ratio of 22.87%

In the past 12 months, SkinBioTherapeutics has paid -72.90K in taxes.

SkinBioTherapeutics EV to EBITDA ratio is -6.17, with an EV/FCF ratio of -5.74.

SkinBioTherapeutics has £1.24M in cash and marketable securities with £1.03M in debt, giving a net cash position of -£210.50K billion.

Gross margin is 54.20%, with operating margin of -240.36%, and net profit margin of -237.95%.

The average price target for SkinBioTherapeutics is £17.00, which is 11.43% higher than the current price. The consensus rating is Hold